Cargando…

Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis

BACKGROUND: Higher serum levels of at least one of a panel of four α-glucose IgM antibodies (gMS-Classifier1) in clinically isolated syndrome (CIS) patients are associated with imminent early relapse within 2 years. OBJECTIVE: The objective of this study was to determine the prognostic value of gMS-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Freedman, MS, Metzig, C, Kappos, L, Polman, CH, Edan, G, Hartung, H-P, Miller, DH, Montalban, X, Yarden, J, Spector, L, Fire, E, Dotan, N, Schwenke, S, Lanius, V, Sandbrink, R, Pohl, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2012
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3546632/ https://www.ncbi.nlm.nih.gov/pubmed/22183938 http://dx.doi.org/10.1177/1352458511432327

Ejemplares similares

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
por: Edan, G, et al.
Publicado: (2014)

Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis
por: Penner, Iris-Katharina, et al.
Publicado: (2012)

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
por: Kappos, Ludwig, et al.
Publicado: (2016)

Molecular mechanism underlying the impact of vitamin D on disease activity of MS
por: Munger, Kassandra L, et al.
Publicado: (2014)

MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome
por: Nielsen, Jessica M, et al.
Publicado: (2009)

Correction: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis
por: Nielsen, Jessica M, et al.
Publicado: (2011)

Serum Biomarker gMS-Classifier2: Predicting Conversion to Clinically Definite Multiple Sclerosis
por: Arrambide, Georgina, et al.
Publicado: (2013)

Anti-α-glucose-based glycan IgM antibodies predict relapse activity in multiple sclerosis after the first neurological event
por: Freedman, MS, et al.
Publicado: (2009)

Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression
por: Röver, Christian, et al.
Publicado: (2015)

Altered individual behavioral and EEG parameters are related to the EDSS score in relapsing-remitting multiple sclerosis patients
por: Vázquez-Marrufo, Manuel, et al.
Publicado: (2019)

Health-related quality of life in multiple sclerosis: temperament outweighs EDSS
por: Salhofer-Polanyi, S., et al.
Publicado: (2018)

Differential diagnosis of suspected multiple sclerosis: a consensus approach
por: Miller, DH, et al.
Publicado: (2008)

Serum Neurofilaments and OCT Metrics Predict EDSS-Plus Score Progression in Early Relapse-Remitting Multiple Sclerosis
por: Tiu, Vlad Eugen, et al.
Publicado: (2023)

Is EDSS Enough to Predict Risk of Upper Urinary Tract Damage in Patients with Multiple Sclerosis?
por: Stritt, Kevin, et al.
Publicado: (2022)

EDSS and infratentorial white matter lesion volume are considered predictors of fatigue severity in RRMS
por: Ezzeldin, Mohammed Y., et al.
Publicado: (2023)

Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5)
por: Lizrova Preiningerova, Jana, et al.
Publicado: (2015)

Static posturography across the EDSS scale in people with multiple sclerosis: a cross sectional study
por: Kalron, Alon, et al.
Publicado: (2016)

Disability status and quality of life in multiple sclerosis: non-linearity of the Expanded Disability Status Scale (EDSS)
por: Twork, Sabine, et al.
Publicado: (2010)

Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration
por: Kearney, H, et al.
Publicado: (2014)

Effect of Vitamin D Supplements on Relapse Rate and Expanded Disability Status Scale (EDSS) in Multiple Sclerosis (MS): A Systematic Review and Meta-Analysis
por: Hanaei, Sara, et al.
Publicado: (2021)

Is Time to Reach EDSS 6.0 Faster in Patients with Late-Onset versus Young-Onset Multiple Sclerosis?
por: Alroughani, Raed, et al.
Publicado: (2016)

Short-term MRI measurements as predictors of EDSS progression in relapsing-remitting multiple sclerosis: grey matter atrophy but not lesions are predictive in a real-life setting
por: von Gumberz, Johanna, et al.
Publicado: (2016)

Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome
por: Meyniel, Claire, et al.
Publicado: (2012)

Cerebral Circulation Time is Prolonged and Not Correlated with EDSS in Multiple Sclerosis Patients: A Study Using Digital Subtracted Angiography
por: Monti, Lucia, et al.
Publicado: (2015)

Variability in detection and quantification of interferon β-1b–induced neutralizing antibodies
por: Hartung, Hans-Peter, et al.
Publicado: (2012)

Correction: Cerebral Circulation Time is Prolonged and Not Correlated with EDSS in Multiple Sclerosis Patients: A Study Using Digital Subtracted Angiography
Publicado: (2015)

EDSS Change Relates to Physical HRQoL While Relapse Occurrence Relates to Overall HRQoL in Patients with Multiple Sclerosis Receiving Subcutaneous Interferon β-1a
por: Vickrey, Barbara G., et al.
Publicado: (2015)

Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis
por: van den Elskamp, I. J., et al.
Publicado: (2010)

Design science: European design science symposium EDSS 2013, Dublin, Ireland, November 21-22, 2013 revised selected papers
por: Helfert, Markus, et al.
Publicado: (2015)

Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis
por: Meyer-Moock, Sandra, et al.
Publicado: (2014)

At the Crossroads of Stewardship and Technology: Impact of Pharmacokinetic-Pharmacodynamic (PK-PD) Integrated Electronic Decision Support Software (EDSS) on the Treatment of Patients Infected with Pneumonia
por: Bader, Justin C, et al.
Publicado: (2017)

Introduction
por: Polman, Chris H., et al.
Publicado: (2007)

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis
por: Freedman, MS, et al.
Publicado: (2015)

Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study
por: Giovannoni, Gavin, et al.
Publicado: (2023)

Symptom-Level Disability Status Assessed with an Electronic Unsupervised Patient-Reported Expanded Disability Status Scale (ePR-EDSS) in Multiple Sclerosis Patients—The Example of Croatia
por: Jerković, Ana, et al.
Publicado: (2022)

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Dimethyl cis-4-hydroxymethylpiperidine-2,6-dicarboxylate
por: Hartung, Jens, et al.
Publicado: (2010)

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study
por: Freedman, Mark S, et al.
Publicado: (2017)

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis
por: Derfuss, T, et al.
Publicado: (2020)

A Maximum Entropy Method for the Prediction of Size Distributions
por: Metzig, Cornelia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d4e4p94j3uapgbs36i1ffrmf70